Bondholder Kenneth Dart, after staying quiet, says he wants full payment—just like Paul Singer
Does SodaStream's turn toward branding itself as a sparkling water vendor—and its dismal financial performance—suggest that it's seeking a different future?
A federal judge in New York refuses to exterminate an asbestos union's inflatable rat, saying "Scabby the Rat" is covered by the First Amendment
In October, more than two customers joined T-Mobile from a competitor for every customer that left it
Dominique Strauss-Kahn acquired a 20 percent stake in a Luxembourg finance firm last year, but quit his chairmanship on Oct. 20. His ex-partner Thierry Leyne died on Oct. 23
Ministry of Supply’s Aviator jacket combines the structure of a tailored garment with the functionality of a windbreaker
Marvel isn't keeping quiet about its movie plans now that DC has publicized its long slate of superhero vehicles
U.S. consumers are more likely to believe marketing materials that include charts and other scientific-looking things
This year's must-have Silicon Valley office accessory: a $199 bear costume
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."